Clinical Research on the Leading Causes of Severe Sight Impairment in the UK General and Working Populations

Overview

Journal Clin Ophthalmol

Publisher Dove Medical Press

Specialty Ophthalmology

Date 2023 Sep 25

PMID 37743890

Authors

Wei Jia Liu

Laura J Taylor

Robert E MacLaren

Jasleen K Jolly

Affiliations

Soon will be listed here.

Abstract

Purpose: Clinical research brings the potential of improved diagnostics, sight-saving treatments, and more accessible services to those suffering with severe sight impairment (SSI). This report investigates whether registered ophthalmology clinical studies address the leading causes of SSI in the general and working populations of the United Kingdom (UK).

Methods: The latest statistics on the leading causes of SSI in the UK general and working populations were identified by searching PubMed, Cochrane Library, and TRIP databases. Clinical study registries were searched to identify registered clinical studies (on or prior to 1st December 2022) on the leading causes of SSI. The relationship between the number of clinical studies on leading causes of SSI and the percentage of SSI certifications they account for was analyzed.

Results: In the UK general population, the number of registered clinical studies on the leading causes of SSI is statistically significantly correlated (Spearman's rho = 0.86, < 0.01) with the percentage of SSI certifications they account for. However, there is no correlation between the two in the UK working population (aged 16-64) (Spearman's rho = 0.15, = 0.70). Eye conditions accounting for the most SSI certifications in individuals of working age have significantly less clinical research activity than those that cause the most SSI certifications in the general population. Out of the leading causes of SSI certifications studied, disorders of the visual cortex and congenital anomalies of the eye have the least clinical research activity.

Conclusion: Clinical research into the leading causes of SSI in the general population is essential. However, it is important to consider eye conditions that cause the most severe visual impairment in individuals of working age due to the significant health and socioeconomic implications of sight loss in this population.

References

Dewing J, Lotery A, Ratnayaka J . The disparity between funding for eye research vs. the high cost of sight-loss in the UK. Eye (Lond). 2022; 37(4):584-586. PMC: 9998460. DOI: 10.1038/s41433-022-02228-7. View

Mitry D, Bunce C, Wormald R, Leamon S, Simkiss P, Cumberland P . Causes of certifications for severe sight impairment (blind) and sight impairment (partial sight) in children in England and Wales. Br J Ophthalmol. 2013; 97(11):1431-6. DOI: 10.1136/bjophthalmol-2013-303578. View

Fortuny C, Flannery J . Mutation-Independent Gene Therapies for Rod-Cone Dystrophies. Adv Exp Med Biol. 2018; 1074:75-81. DOI: 10.1007/978-3-319-75402-4_10. View

Sun Y, Chen A, Zou M, Zhang Y, Jin L, Li Y . Time trends, associations and prevalence of blindness and vision loss due to glaucoma: an analysis of observational data from the Global Burden of Disease Study 2017. BMJ Open. 2022; 12(1):e053805. PMC: 8739070. DOI: 10.1136/bmjopen-2021-053805. View

Sahel J, Bennett J, Roska B . Depicting brighter possibilities for treating blindness. Sci Transl Med. 2019; 11(494). DOI: 10.1126/scitranslmed.aax2324. View

Marques A, Ramke J, Cairns J, Butt T, Zhang J, Muirhead D . Global economic productivity losses from vision impairment and blindness. EClinicalMedicine. 2021; 35:100852. PMC: 8093883. DOI: 10.1016/j.eclinm.2021.100852. View

Rahi J, Cable N . Severe visual impairment and blindness in children in the UK. Lancet. 2003; 362(9393):1359-65. DOI: 10.1016/S0140-6736(03)14631-4. View

Yonekawa Y, Miller J, Kim I . Age-Related Macular Degeneration: Advances in Management and Diagnosis. J Clin Med. 2015; 4(2):343-59. PMC: 4470128. DOI: 10.3390/jcm4020343. View

Tanna P, Strauss R, Fujinami K, Michaelides M . Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options. Br J Ophthalmol. 2016; 101(1):25-30. PMC: 5256119. DOI: 10.1136/bjophthalmol-2016-308823. View

10.

Bunce C, Zekite A, Wormald R, Bowman R . Is there evidence that the yearly numbers of children newly certified with sight impairment in England and Wales has increased between 1999/2000 and 2014/2015? A cross-sectional study. BMJ Open. 2017; 7(9):e016888. PMC: 5588960. DOI: 10.1136/bmjopen-2017-016888. View

11.

Schwartz S, Regillo C, Lam B, Eliott D, Rosenfeld P, Gregori N . Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. 2014; 385(9967):509-16. DOI: 10.1016/S0140-6736(14)61376-3. View

12.

Barry R, Murray P . Unregistered visual impairment: is registration a failing system?. Br J Ophthalmol. 2005; 89(8):995-8. PMC: 1772775. DOI: 10.1136/bjo.2004.059915. View

13.

Burton M, Ramke J, Marques A, Bourne R, Congdon N, Jones I . The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. Lancet Glob Health. 2021; 9(4):e489-e551. PMC: 7966694. DOI: 10.1016/S2214-109X(20)30488-5. View

14.

Samuelson T, Chang D, Marquis R, Flowers B, Sheng Lim K, Ahmed I . A Schlemm Canal Microstent for Intraocular Pressure Reduction in Primary Open-Angle Glaucoma and Cataract: The HORIZON Study. Ophthalmology. 2018; 126(1):29-37. DOI: 10.1016/j.ophtha.2018.05.012. View

15.

Thompson D, Iannaccone A, Ali R, Arshavsky V, Audo I, Bainbridge J . Advancing Clinical Trials for Inherited Retinal Diseases: Recommendations from the Second Monaciano Symposium. Transl Vis Sci Technol. 2020; 9(7):2. PMC: 7414644. DOI: 10.1167/tvst.9.7.2. View

16.

Jonas J, Aung T, Bourne R, Bron A, Ritch R, Panda-Jonas S . Glaucoma. Lancet. 2017; 390(10108):2183-2193. DOI: 10.1016/S0140-6736(17)31469-1. View

17.

Sahel J, Boulanger-Scemama E, Pagot C, Arleo A, Galluppi F, Martel J . Partial recovery of visual function in a blind patient after optogenetic therapy. Nat Med. 2021; 27(7):1223-1229. DOI: 10.1038/s41591-021-01351-4. View

18.

Quartilho A, Simkiss P, Zekite A, Xing W, Wormald R, Bunce C . Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013. Eye (Lond). 2016; 30(4):602-7. PMC: 5108547. DOI: 10.1038/eye.2015.288. View

19.

Ittoop S, Seibold L, Kahook M . Current opinion in ophthalmology: novel glaucoma devices in the pipeline. Curr Opin Ophthalmol. 2018; 30(2):117-124. DOI: 10.1097/ICU.0000000000000555. View

20.

Liew G, Michaelides M, Bunce C . A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010. BMJ Open. 2014; 4(2):e004015. PMC: 3927710. DOI: 10.1136/bmjopen-2013-004015. View